01 Gaozhi Pharmaceutical's Benidipine Hydrochloride Tablets Officially Approved

On April 2, 2025, Zhejiang Gaozhi Pharmaceutical received the Drug Registration Certificate for Benidipine Hydrochloride Tablets issued by the National Medical Products Administration (NMPA) of China. Approval numbers and specifications are as follows:

National Drug Approval Number: H20253691; Specification: 4mg
National Drug Approval Number: H20253692; Specification: 8mg
With this, Benidipine Hydrochloride Tablets of Zhejiang Gaozhi Pharmaceutical has been officially approved for marketing.

Benidipine Hydrochloride Tablets is classified as Category B of the National Medical Insurance Catalog. Its main component is benidipine, which is indicated for the treatment of essential hypertension and angina pectoris. As a dihydropyridine calcium channel blocker, benidipine selectively blocks L/N/T-type calcium channels on vascular smooth muscle cells, inhibits calcium ion influx, dilates peripheral arteries and coronary arteries, reduces peripheral vascular resistance and coronary vascular resistance, and weakens myocardial contraction—thereby achieving the effects of lowering blood pressure and treating angina pectoris.

According to data from Mi Nei Wang (a leading pharmaceutical information service platform in China), the sales volume of benidipine hydrochloride tablets has shown a steady growth trend in recent years. In 2023, its hospital market scale reached approximately RMB 900 million, retail market scale exceeded RMB 200 million, and the overall market scale surpassed RMB 1.1 billion.

As indicated in the Report on Cardiovascular Health and Diseases in China, the number of people currently suffering from cardiovascular diseases (CVD) in China is 330 million, including 245 million hypertension patients and 11.39 million coronary heart disease patients. These figures have been on a continuous rise in recent years, imposing a heavy burden on families and society. It can thus be seen that the market demand for benidipine hydrochloride tablets presents a stable growth trend and enjoys promising market prospects.

02 Hippocrates's eMAH Digital Solution: Escorting Gaozhi Pharmaceutical

Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. has extensively adopted Xingdi's "Collaborative Solution for Contract Manufacturing Quality Management" (referred to as eMAH). This solution has helped Gaozhi Pharmaceutical establish a comprehensive quality management framework, ensuring that the entire process of pharmaceuticals—from the initiation of R&D to the realization of production—strictly complies with regulatory standards.

Through the implementation of the eMAH project, Gaozhi Pharmaceutical has successfully built a complete quality management system, enabling efficient sharing and real-time transmission of quality documents, associated records, and reports. This system has significantly streamlined approval and release processes, effectively enhancing the company's quality management efficiency in pharmaceutical contract manufacturing.

Meanwhile, Hippocrates's digital platform "OwlTrust" has injected strong technical impetus into Gaozhi Pharmaceutical, ensuring that data is real-time, accurate, and reliable. By virtue of online monitoring and real-time early warning functions, the platform further strengthens the online control of pharmaceutical quality.

Hippocrates's eMAH solution has provided solid support for the successful market launch of Gaozhi Pharmaceutical's products. From R&D to production, from quality control to market access, Hippocrates's professional technologies and services run through the entire process, safeguarding the pharmaceutical quality of Gaozhi Pharmaceutical.

03 Introduction to Both Parties

About Gaozhi Pharmaceutical

Zhejiang Gaozhi Pharmaceutical Technology Co., Ltd. specializes in pharmaceutical R&D, pharmaceutical production, pharmaceutical wholesale and retail, and technical services. Integrating "R&D, production, and sales" into one, the company obtained the Drug Production License in August 2021 and passed the Drug GMP Compliance Inspection in December 2021.

Up to now, Gaozhi Pharmaceutical has initiated over 100 pharmaceutical R&D projects, obtained 12 Drug Registration Certificates, 4 invention patents, and 2 design patents. It is expected that more than 50 pharmaceutical specifications will be approved by 2025.

Since its establishment three years ago, the company has successively obtained certifications including "Zhejiang Provincial Technology-Based SME", "National Technology-Based SME", "Innovative SME", "2023 Potential Unicorn Enterprise", "2023 Hangzhou Headquarters Enterprise", "2024 Potential Unicorn Enterprise", "2024 Hangzhou Headquarters Enterprise", and "Zhejiang Excellent Private Enterprise". In 2022, with an annual output value of RMB 135 million, it became a designated large-scale biomedical industrial enterprise in Hangzhou.

Relying on its abundant reserve of R&D products, reliable product quality, and precise market positioning, Gaozhi Pharmaceutical now has its products sold in 30 provinces, municipalities, and autonomous regions across China, and is rapidly emerging in the industry.

About Hippocrates

The name "Hippocrates" is the phonetic translation of "Hippocrates"—the "Father of Medicine" in ancient Greece. Hippocrates is a leading provider of digital solutions in China's life and health industry. It is committed to helping enterprises in the life and health sector (including pharmaceuticals, medical devices, and cosmetics) achieve digital transformation through innovative technologies and products.

The company's business covers GMP quality management, digital factory construction, GVP pharmacovigilance, GCP clinical research, and other fields. It has served over 200 clients in China, established overseas branches, and formed cooperative relationships with a number of multinational enterprises.